Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | F10 | P00742 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4332278 | 0.88 | MAOB (0.48) | MAOBLMNAGLAMAPTHCAR2 | |
| SCHEMBL68412 | 0.88 | L3MBTL1 (0.50) | MAOBMAPTF10SMN1; SMN2L3MBTL1 | |
| SCHEMBL16960161 | 0.85 | MAOB (0.47) | MAOBLMNAGLAMAPTHCAR2 | |
| SCHEMBL1624525 | 0.84 | PPID (0.50) | MAOBMAPTL3MBTL1NPC1RAB9A | |
| SCHEMBL901475 | 0.84 | CYP4F2 (0.55) | MAOBLMNAGLAMAPTNPC1 | |
| SCHEMBL4707684 | 0.84 | MAPT (0.49) | MAOBLMNAGLAMAPTHCAR2 | |
| SCHEMBL12020856 | 0.83 | SMN1; SMN2 (0.45) | MAOBMAPTF10SMN1; SMN2L3MBTL1 | |
| SCHEMBL30692683 | 0.83 | SLC7A5 (0.55) | MAOBMAPTNPC1RAB9A | |
| SCHEMBL1107143 | 0.83 | KMT2A (0.56) | MAOBSMN1; SMN2L3MBTL1NPC1PKM | |
| SCHEMBL74878 | 0.83 | SLC7A5 (0.55) | MAOBMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3268360-B1 | LACTAMS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-3268360-B1 | LACTAMS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2019-04-24 | — | — | EP | disclosed |
| US-10112929-B2 | Lactams as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-10-30 | — | — | US | disclosed |
| CN-108250128-A | Compound as potassium channel modulating agents | 江苏先声药业有限公司 | 2018-07-06 | — | — | CN | disclosed |
| US-20180044326-A1 | LACTAMS AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMAPANY (US) | 2018-02-15 | — | — | US | disclosed |
| US-20180044326-A1 | LACTAMS AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMAPANY (US) | 2018-02-15 | — | — | US | disclosed |
| US-20180044326-A1 | LACTAMS AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMAPANY (US) | 2018-02-15 | — | — | US | disclosed |
| EP-3268360-A1 | LACTAMS AS INHIBITORS OF ROCK | Bristol-Myers Squibb Company (US) | 2018-01-17 | — | — | EP | disclosed |
| CN-103183674-B | One class fused heterocyclic derivative and its application | 江苏先声药业有限公司 | 2017-09-12 | — | — | CN | disclosed |
| CN-103502213-B | Alkaloid ester and carbamate derivatives thereof and medicinal compositions | 奇斯药制品公司 | 2016-09-28 | — | — | CN | disclosed |
| US-6310208-B1 | Serotonin receptor binding benzo[e]isoindoles and benzo[h]isoquinolines | HOFFMANN-LA ROCHE INC. | 2001-10-30 | — | — | US | disclosed |
| CN-1312803-A | Novel benzopyran or benzothiopyran derivatives | C & C RES LAB (KR) | 2001-09-12 | — | — | CN | disclosed |
| EP-1087959-A1 | NOVEL BENZOPYRAN OR THIOBENZOPYRAN DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065893-A1 | NOVEL BENZOPYRAN OR THIOBENZOPYRAN DERIVATIVES | C & C RESEARCH LABORATORIES (KR) | 1999-12-23 | — | — | WO | disclosed |
| EP-0958285-A1 | TRICYCLIC BENZO[e]ISOINDOLES AND BENZO[h]ISOQUINOLINES | F.HOFFMANN-LA ROCHE AG (CH) | 1999-11-24 | — | — | EP | disclosed |
| WO-1998030546-A1 | TRICYCLIC BENZO[e]ISOINDOLES AND BENZO[h]ISOQUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 1998-07-16 | — | — | WO | disclosed |
| US-4435419-A | Method of treating depression using azabicyclohexanes | AMERICAN CYANAMID COMPANY (US) | 1984-03-06 | — | — | US | disclosed |
| US-4231935-A | ANXIOLYTICS AND ANALGESICS | AMERICAN CYANAMID COMPANY (US) | 1980-11-04 | — | — | US | disclosed |
| US-4196120-A | 1,2-BIS(HYDROCARBYLSULFONYLOXY OR HALO METHYL)CYCLOPROPYLBENZENE, OPTICAL ACITIVITY ANALGESICS | AMERICAN CYANAMID COMPANY (US) | 1980-04-01 | — | — | US | disclosed |
| US-4131611-A | ANXIOLYTIC, ANALGESIC | AMERICAN CYANAMID COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044326-A1 | LACTAMS AS INHIBITORS OF ROCK | MYLK, ROCK1, RHOA | MAOB 1999/4885LMNA 1739/4885GLA 1160/4885 |
| US-10112929-B2 | Lactams as inhibitors of rock | MYLK, ROCK1, RHOA | MAOB 2095/4885LMNA 1791/4885GLA 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.